Omaha.com11d
Sarepta’s Gene Therapy Under Scrutiny After Patient Death
Elevidys, which costs $3.2 million for a one-time infusion, was the first gene therapy approved in the U.S. for Duchenne ...
Patient dies following muscular dystrophy gene therapy, Sarepta reports
A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...
The Pharma Letter11d
Alarm over Elevidys patient death
Genetic medicine firm Sarepta Therapeutics announced the tragic death of a young man with Duchenne muscular dystrophy (DMD) ...
Business Insider11d
Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)
With revenues climbing steadily since 2022, Sarepta is just beginning to reap the benefits of Elevidys’ commercialization. In its most recent quarter, SRPT’s cost of sales was $132.3 million, while ...
KTBS11d
Sarepta’s Gene Therapy Under Scrutiny After Patient Death
Elevidys, which costs $3.2 million for a one-time infusion, was the first gene therapy approved in the U.S. for Duchenne muscular dystrophy, a rare condition that causes muscle weakness ...
Morning Call PA12d
Patient dies following muscular dystrophy gene therapy, Sarepta reports
Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 million for a one-time treatment. Sarepta has received FDA accelerated ...